| 000 | 01211 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518005049.0 | ||
| 264 | 0 | _c20191018 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdy492 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaurer, M J | |
| 245 | 0 | 0 |
_aReply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _c01 2019 |
||
| 300 |
_a153 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Research Support, Non-U.S. Gov't; Comment | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLymphoma, Large B-Cell, Diffuse |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRituximab |
| 700 | 1 | _aHabermann, T M | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 30 _gno. 1 _gp. 153 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdy492 _zAvailable from publisher's website |
| 999 |
_c29011534 _d29011534 |
||